Pneumococcal 15-Valent Conjugate Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Oct 3, 2023.

Usual Adult Dose for Pneumococcal Disease Prophylaxis

0.5 mL IM once

Use: Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33

Usual Pediatric Dose for Pneumococcal Disease Prophylaxis

0.5 mL IM as a 4 dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the third dose)
0.5 mL IM as a 3 dose series at 7 through 11 months of age (the first 2 doses are given at least 4 weeks apart; third dose given after the one-year birthday, separated from the second dose by at least 2 months)
0.5 mL IM as a 2 dose series at 12 through 23 months of age (two doses at least 2 months apart)
0.5 mL IM once to 2 through 17 years of age (and at least 2 months after the third dose)

Comments:

• The first dose can be initiated at as early as 6 weeks of age.
• The 4-dose series started with a lower valency pneumococcal conjugate vaccine can be completed with this vaccine.
• Children and adolescents 2 years through 17 years of age who have received an incomplete series of another pneumococcal conjugate vaccine can be administered this vaccine in a single dose with a gap of at least 2 months from the last dose of another pneumococcal conjugate vaccine.

Use: Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
Severe allergic reaction (e.g. anaphylaxis) to any ingredient or to diphtheria toxoid

Safety and efficacy have not been established in patients younger than 6 weeks.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration:

• For intramuscular administration only.

Storage requirements:

• Refrigerate; do not freeze.
• Protect from light.

Reconstitution/preparation techniques:

• Hold prefilled syringe horizontally and shake vigorously to obtain an opalescent suspension immediately prior to use.
• Do not use if vaccine cannot be resuspended.

Patient advice:

• Patients should be informed about the potential benefits and risks of immunization with this drug.
• Patients should report any suspected adverse reactions to their health care professional.
• This vaccine may not protect all recipients.
• Patients should be informed about importance of completing the vaccination series unless contraindicated.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer